Cambridge Cognition Reports Growth and Strategic Advancements in 2024

Cambridge Cognition Holdings ( (GB:COG) ) just unveiled an update.

Cambridge Cognition Holdings reported its preliminary unaudited results for the year ending December 2024, highlighting a revenue of £10.3m, a reduction in operating costs, and an improved adjusted EBITDA loss. The company has taken significant steps to return to growth, including rebuilding its commercial team and revising its strategy to focus on long-term relationships with larger pharmaceutical and biotech companies. With a strong start to 2025, Cambridge Cognition anticipates delivering £8.5m in revenue from its current order book, aiming for sustained profitability and growth in equity value. The company has also made advancements in product and technology, including launching a new Rater Training service and securing a grant for cognitive assessments.

More about Cambridge Cognition Holdings

Cambridge Cognition Holdings is a brain health software group specializing in digital health products aimed at advancing brain health research and treatment. The company leverages rich, curated data and technical expertise to build a global brand with scalable technology. It focuses on four market sectors: Clinical Studies, Academic Research, Healthcare, and Consumer Health & Wellness, providing cognitive assessments through digital and voice-based tools.

YTD Price Performance: -4.00%

Average Trading Volume: 19,743

Technical Sentiment Signal: Strong Buy

Current Market Cap: £15.07M

Find detailed analytics on COG stock on TipRanks’ Stock Analysis page.